OutSee

Executive Summary

OutSee is a UK-based biotechnology company founded in 2020 that leverages artificial intelligence and fundamental biology to advance genomic discovery. Its core platform, Nomaly, is a predictive AI engine designed to interpret individual genomes and uncover disease mechanisms and phenotypes from first principles, offering novel insights beyond traditional association-based analyses. As a discovery platform, OutSee aims to extract novel biological insights that can drive drug target identification and precision medicine. Operating in the competitive genomics and AI space, the company has yet to disclose funding rounds, valuation, or specific milestones, suggesting it is at a relatively early stage. The company's unique approach of combining AI with fundamental biology positions it to potentially address limitations in current genomic analysis methods. However, the lack of public traction, partnerships, or revenue-generating products results in an uncertain near-term outlook. The success of OutSee hinges on its ability to validate its platform through collaborations or proprietary discoveries, attract investment, and demonstrate clinical or commercial utility. The following conviction score reflects the early stage and limited public information.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Announcement60% success
• Q4 2026Pharmaceutical Partnership for Target Discovery40% success
• Q3 2026Publication of Validation Study in Peer-Reviewed Journal50% success